MX380578B - Derivados de imidazol pentaciclicos fusionados. - Google Patents
Derivados de imidazol pentaciclicos fusionados.Info
- Publication number
- MX380578B MX380578B MX2017004201A MX2017004201A MX380578B MX 380578 B MX380578 B MX 380578B MX 2017004201 A MX2017004201 A MX 2017004201A MX 2017004201 A MX2017004201 A MX 2017004201A MX 380578 B MX380578 B MX 380578B
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- imidazole derivatives
- fused pentacyclic
- pentacyclic imidazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290299 | 2014-10-03 | ||
| EP15162641 | 2015-04-07 | ||
| EP15171036 | 2015-06-08 | ||
| PCT/EP2015/072868 WO2016050975A1 (en) | 2014-10-03 | 2015-10-02 | Fused pentacyclic imidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004201A MX2017004201A (es) | 2017-05-30 |
| MX380578B true MX380578B (es) | 2025-03-12 |
Family
ID=54238452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004201A MX380578B (es) | 2014-10-03 | 2015-10-02 | Derivados de imidazol pentaciclicos fusionados. |
Country Status (36)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380578B (es) * | 2014-10-03 | 2025-03-12 | Ucb Biopharma Sprl | Derivados de imidazol pentaciclicos fusionados. |
| EP3288939A1 (en) | 2015-04-17 | 2018-03-07 | AbbVie Inc. | Tricyclic modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| EA201892153A1 (ru) * | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |
| JP6968090B2 (ja) * | 2016-04-01 | 2021-11-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
| EP3436458B1 (en) | 2016-04-01 | 2021-06-02 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| US10766906B2 (en) | 2016-04-01 | 2020-09-08 | UCB Biopharma SRL | Fused hexacyclic imidazole derivatives as modulators of TNF activity |
| GB201620948D0 (en) | 2016-12-09 | 2017-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110461842A (zh) * | 2017-03-15 | 2019-11-15 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
| AU2018259040B2 (en) * | 2017-04-25 | 2022-04-28 | Sanofi | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
| MX2020010433A (es) * | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| CA3117344A1 (en) | 2018-10-24 | 2020-04-30 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| CN120418259A (zh) * | 2022-11-23 | 2025-08-01 | 弗沃德医疗公司 | TNFα活性的调节剂 |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| TW202508596A (zh) | 2023-04-26 | 2025-03-01 | 法商賽諾菲公司 | 使用腫瘤壞死因子α之小分子抑制劑治療乾癬 |
| WO2024251282A1 (zh) * | 2023-06-09 | 2024-12-12 | 上海翰森生物医药科技有限公司 | 五环类衍生物抑制剂、其制备方法和应用 |
| TW202521544A (zh) * | 2023-08-16 | 2025-06-01 | 美商雷瑟拉股份有限公司 | TNFα活性調節劑及其用途 |
| WO2025068505A1 (en) | 2023-09-29 | 2025-04-03 | Sanofi | Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation |
| WO2025137267A1 (en) * | 2023-12-21 | 2025-06-26 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| TW202602881A (zh) * | 2024-03-27 | 2026-01-16 | 大陸商海思科醫藥集團股份有限公司 | 雜環衍生物及其在醫藥上的應用 |
| WO2025212627A1 (en) * | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025218735A1 (zh) * | 2024-04-17 | 2025-10-23 | 上海翰森生物医药科技有限公司 | 五环类衍生物抑制剂、其制备方法和应用 |
| WO2025240514A1 (en) * | 2024-05-15 | 2025-11-20 | Forward Therapeutics, Inc. | Treatment of autoimmune or inflammatory disease |
| WO2025244936A1 (en) * | 2024-05-20 | 2025-11-27 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025247401A1 (zh) * | 2024-05-31 | 2025-12-04 | 海思科医药集团股份有限公司 | 一种稠合杂环衍生物及其在医药上的应用 |
| WO2025255096A1 (en) * | 2024-06-03 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Cycloalkyl and heterocyclic modulators of tnf activity |
| WO2025252251A1 (zh) * | 2024-06-07 | 2025-12-11 | 上海翰森生物医药科技有限公司 | 含氧杂环类衍生物抑制剂、其制备方法和应用 |
| WO2026022134A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Novel aminocarbonylation processes |
| WO2026021586A1 (zh) * | 2024-07-26 | 2026-01-29 | 上海瀚辰星泰医药科技有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2026027449A1 (en) | 2024-07-29 | 2026-02-05 | Sanofi | Fused pentacyclic imidazole derivatives |
| WO2026051930A1 (zh) * | 2024-09-04 | 2026-03-12 | 苏州湃玥生物科技有限公司 | 一种作为tnf活性调节剂的稠合五环苯并咪唑衍生物及其制备方法和应用 |
| WO2026055519A1 (en) | 2024-09-06 | 2026-03-12 | Rapt Therapeutics, Inc. | Fused ring imidazole compounds |
| WO2026068677A1 (en) * | 2024-09-27 | 2026-04-02 | Sanofi | Processes for the preparation of fused pentacyclic imidazoles and intermediates |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449649A3 (en) | 1990-03-30 | 1992-09-02 | Arizona Board Of Regents, Arizona State University | Antineoplastic quinones and methods of using same |
| FR2832711B1 (fr) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| BRPI0408477A (pt) | 2003-03-10 | 2006-04-04 | Pfizer | compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| CN103702994B (zh) | 2011-06-20 | 2016-03-23 | 沃泰克斯药物股份有限公司 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
| US9550737B2 (en) * | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| CN104619709B (zh) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| RU2744460C2 (ru) | 2014-04-15 | 2021-03-09 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости |
| MX380578B (es) * | 2014-10-03 | 2025-03-12 | Ucb Biopharma Sprl | Derivados de imidazol pentaciclicos fusionados. |
-
2015
- 2015-10-02 MX MX2017004201A patent/MX380578B/es unknown
- 2015-10-02 AP AP2017009809A patent/AP2017009809A0/en unknown
- 2015-10-02 CA CA2962826A patent/CA2962826C/en active Active
- 2015-10-02 MA MA40770A patent/MA40770B1/fr unknown
- 2015-10-02 HR HRP20211605TT patent/HRP20211605T1/hr unknown
- 2015-10-02 EA EA201790734A patent/EA032839B1/ru not_active IP Right Cessation
- 2015-10-02 PE PE2017000544A patent/PE20170693A1/es unknown
- 2015-10-02 TN TN2017000083A patent/TN2017000083A1/en unknown
- 2015-10-02 UY UY0001036341A patent/UY36341A/es not_active Application Discontinuation
- 2015-10-02 CN CN201580053711.8A patent/CN107108672B/zh active Active
- 2015-10-02 HU HUE15771976A patent/HUE056133T2/hu unknown
- 2015-10-02 CR CR20170167A patent/CR20170167A/es unknown
- 2015-10-02 AU AU2015326798A patent/AU2015326798B2/en active Active
- 2015-10-02 SI SI201531711T patent/SI3201196T1/sl unknown
- 2015-10-02 ES ES15771976T patent/ES2885432T3/es active Active
- 2015-10-02 RS RS20211235A patent/RS62423B1/sr unknown
- 2015-10-02 SG SG11201701796XA patent/SG11201701796XA/en unknown
- 2015-10-02 LT LTEPPCT/EP2015/072868T patent/LT3201196T/lt unknown
- 2015-10-02 MY MYPI2017701132A patent/MY181019A/en unknown
- 2015-10-02 BR BR112017006669-6A patent/BR112017006669B1/pt active IP Right Grant
- 2015-10-02 US US15/513,357 patent/US10202405B2/en active Active
- 2015-10-02 WO PCT/EP2015/072868 patent/WO2016050975A1/en not_active Ceased
- 2015-10-02 KR KR1020177011958A patent/KR102442235B1/ko active Active
- 2015-10-02 TW TW104132631A patent/TWI719949B/zh active
- 2015-10-02 UA UAA201702002A patent/UA120764C2/uk unknown
- 2015-10-02 EP EP15771976.6A patent/EP3201196B1/en active Active
- 2015-10-02 PL PL15771976T patent/PL3201196T3/pl unknown
- 2015-10-02 JP JP2017518131A patent/JP6629847B2/ja active Active
- 2015-10-02 DK DK15771976.6T patent/DK3201196T3/da active
-
2017
- 2017-03-06 PH PH12017500414A patent/PH12017500414B1/en unknown
- 2017-03-07 GT GT201700044A patent/GT201700044A/es unknown
- 2017-03-14 IL IL251147A patent/IL251147B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01946A patent/ZA201701946B/en unknown
- 2017-03-31 CL CL2017000787A patent/CL2017000787A1/es unknown
- 2017-04-06 CO CONC2017/0003331A patent/CO2017003331A2/es unknown
- 2017-05-03 EC ECIEPI201727306A patent/ECSP17027306A/es unknown
-
2018
- 2018-12-14 US US16/220,847 patent/US10906919B2/en active Active
-
2020
- 2020-11-24 US US17/102,790 patent/US11912721B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380578B (es) | Derivados de imidazol pentaciclicos fusionados. | |
| PH12019502182A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| BR112016012997A2 (pt) | Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112016012990A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112016013012A2 (pt) | Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf | |
| BR112018069936A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf | |
| BR112018069937A2 (pt) | derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf | |
| BR112016012261A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| CA2931589C (en) | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity | |
| EA201500130A1 (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| BR112016011484A2 (pt) | Derivados de imidazopirimidina como moduladores de atividade de tnf | |
| BR112016011794A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| BR112016012242A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf | |
| BR112016012243A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| BR112016011792A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| BR112016011483A2 (pt) | Derivados de imidazotriazina como moduladores de atividade de tnf | |
| BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
| BR112016011485A2 (pt) | Derivados de imidazopiridazina como moduladores de atividade de tnf | |
| BR112016012253A2 (pt) | Compostos derivados de imidazol e pirazol, composição farmacêutica e uso dos compostos | |
| EA201500133A1 (ru) | Производные имидазопиразина в качестве модуляторов активности tnf | |
| BR112018069941A2 (pt) | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf | |
| BR112016012254A2 (pt) | Derivados de triazolpiridazina como moduladores de atividade de tnf | |
| BR112016011527A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| TR201910983T4 (tr) | Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. | |
| BR112016013007A2 (pt) | Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf |